Table 1.

Incidence of grade 3 and 4 adverse events (%) in mCRC treatments¹⁹

Parameter	TREE-1 (n = 150)	TREE-2 (n = 223)
Nausea/vomiting	38	21
Diarrhea	31	19
Dehydration	27	8
Paresthesia	21	11
Hand–foot syndrome	19	10
Fatigue	6	11
Anemia	6	0
Leukopenia	2	0
Hypertension	2	15

Adapted from Hochster et al¹⁹, with permission © 2008 American Society of Clinical Oncology.

Abbreviation: mCRC, metastatic colorectal cancer.